MIRACLE

An acute myeloid leukemia research setting illustrates Moleculin Biotech’s Annamycin trial and its 37% blinded remission signal in resistant AML after venetoclax treatment. Representative image.

Moleculin reports 37% blinded remission rate as Annamycin AML trial nears critical readout

by Venkatesh B
August 2, 2026
0 Comments

Moleculin Biotech has reported a preliminary 37% composite complete remission rate among 62 evaluable patients in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine for relapsed or refractory acute myeloid leukemia. The July 31 update also showed a 24% complete remission rate across the blinded study population. Among 30 evaluable

$Representative image: Hematology researchers analyze blood samples as Moleculin’s $MBRX MIRACLE trial reports a 37% blinded composite remission rate in relapsed or refractory acute myeloid leukemia, including patients who previously failed venetoclax.$